We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
- Authors
Maini, R; St Clair, E W; Breedveld, F; Furst, D; Kalden, J; Weisman, M; Smolen, J; Emery, P; Harriman, G; Feldmann, M; Lipsky, P
- Abstract
Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate.
- Publication
Lancet (London, England), 1999, Vol 354, Issue 9194, p1932
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/s0140-6736(99)05246-0